The inorganic nitrate and exercise performance in heart failure (inix-HF): - a phase II clinical trial
Active Project Grant Awarded Last action
- Award ID
- R33HL155858
- Recipient
-
The Washington University UEI L6NFUM28LQM5
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,607,120
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 85% complete
- Place of performance
- St. Louis, MO 63110, USA
Award details come from USAspending.gov.
Description
- Abstract
- Heart failure with reduced ejection fraction (hfref) affects ~3 million people in the U.S. And is a mortal and morbid disease. Hfref impairs a patient's ability to exercise and perform activities of daily living. Although weak cardiac pumping ability clearly contributes to chronic disability associated with hfref, abnormal skeletal muscle function in patients with hfref is also a key debilitating factor. Skeletal muscle is therefore a vital target for treatment of hfref. Dietary inorganic nitrate enhances aerobic exercise capacity and muscle power in patients with hfref, as demonstrated in our preliminary studies. The overarching aim of the proposed clinical trial is to determine whether inorganic nitrate in a once-a-day oral gelcap format, offers a new, safe, and effective treatment for ameliorating the impaired exercise performance due to hfref. The aim of the R61 component of this grant is to set up the infrastructure necessary for the phase II clinical trial and to begin the trial. This includes compounding the inorganic nitrate (KNO3)/placebo capsules and all safety testing, obtaining institutional review board approval, clinicaltrials.GOV registration, redcap database development, recruitment enhancement core (REC) engagement, clinical translational research unit (ctru) project approval, enrollment and assessment and dose administration of the first subjects. The aims of the R33 component are to determine the effectiveness of acute (2 hours after a single dose) and chronic (after 6 weeks of once-a-day dosing) KNO3 treatment (10MMOL) VS. Placebo on quadriceps muscle power and on aerobic exercise performance (VO2PEAK) in patients with hfref (left ventricular ejection fraction
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $708,812 | |
| Amendment | $740,803 | |
| Amendment | $0 | |
| Amendment | $341,565 | |
| Amendment | $341,565 | |
| Amendment | $737,188 | |
| Original award | $737,188 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Trustees Of Indiana University | $155,988 | |
| Saint Louis University | $8,334 | |
| Arizona State University | $12,083 | |
| Arizona State University | $2,591 | |
| Trustees Of Indiana University | $125,301 | |
| Saint Louis University | $9,090 | |
| Arizona State University | $12,337 | |
| Saint Louis University | $9,090 | |
| Arizona State University | $11,904 | |
| Trustees Of Indiana University | $159,684 |
Quick answers
Who received award R33HL155858?
R33HL155858 was awarded to The Washington University by National Heart Lung and Blood Institute (National Institutes of Health) on August 1, 2022.
How much is award R33HL155858 worth?
$3,607,120 has been obligated on R33HL155858.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award